表观遗传学全球市场规模、份额、趋势和成长分析报告（2026-2034）

预计表观遗传学市场将从 2025 年的 288 亿美元成长到 2034 年的 1,562.6 亿美元，2026 年至 2034 年的复合年增长率为 20.67%。

全球表观遗传学市场正经历快速成长，这主要得益于对基因表现和疾病机制研究的不断深入。表观遗传学研究的是环境因素和化学修饰如何在不改变DNA序列的情况下影响基因活性。随着人们对个人化医疗的日益关注以及分子生物学技术的进步，表观遗传学在疾病诊断、药物研发和治疗方法开发等领域的应用正显着扩展，遍及整个医疗保健行业。

多种因素正在推动表观遗传学市场的扩张。癌症、心血管疾病和神经系统疾病等慢性病的日益普遍，增加了对先进诊断工具和标靶治疗的需求。此外，基因组技术的不断进步，包括定序和生物资讯学，使研究人员能够更有效地研究表观遗传修饰。政府资助以及研究机构与生物技术公司之间合作的加强也促进了市场成长。

随着对基因表现调控的科学认识不断加深，表观遗传学市场预计将稳定成长。表观遗传疗法和精准医疗方法的发展有望革新复杂疾病的治疗策略。此外，生物技术研发投入的增加以及表观遗传生物标记临床应用的不断拓展，预计将为市场带来创新和长期成长机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球表观遗传学市场：依产品划分

• 市场分析、洞察与预测
• 酵素
• 设备和耗材
• 成套工具
• 试剂

第五章：全球表观遗传学市场：依应用领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 非肿瘤区域

第六章 全球表观遗传学市场：依技术划分

• 市场分析、洞察与预测
• DNA甲基化
• 组蛋白甲基化
• 组蛋白乙酰化
• 大型非编码RNA
• 微型RNA修饰
• 染色质结构

第七章 全球表观遗传学市场：依最终使用者划分

• 市场分析、洞察与预测
• 学术研究机构
• 製药公司和生技公司
• 受託研究机构（CRO）

第八章 全球表观遗传学市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific Inc
  • F. Hoffmann La Roche Ltd
  • Novartis AG
  • Merck KGaA
  • Illumina Inc
  • Qiagen NV
  • Pacific Biosciences Of California Inc
  • Bio Techne Corporation
  • Promega Corporation
  • Zymo Research Corporation
  • New England Biolabs Inc
  • Abcam Plc
  • Active Motif Inc
  • Diagenode SA
  • GeneTex Inc

The Epigenetics Market size is expected to reach USD 156.26 Billion in 2034 from USD 28.80 Billion (2025) growing at a CAGR of 20.67% during 2026-2034.

The global epigenetics market has witnessed rapid growth due to increasing research activities focused on understanding gene expression and disease mechanisms. Epigenetics studies how environmental factors and chemical modifications influence gene activity without altering the DNA sequence. Growing interest in personalized medicine and advancements in molecular biology technologies have significantly expanded the applications of epigenetics in disease diagnosis, drug discovery, and therapeutic development across the healthcare sector.

Several factors are driving the expansion of the epigenetics market. Rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions has increased demand for advanced diagnostic tools and targeted treatments. Additionally, continuous advancements in genomic technologies, including sequencing and bioinformatics, are enabling researchers to study epigenetic modifications more effectively. Government funding and increasing collaboration between research institutions and biotechnology companies are also supporting market growth.

In the future, the epigenetics market is expected to grow steadily as scientific understanding of gene regulation continues to improve. The development of epigenetic therapies and precision medicine approaches may transform treatment strategies for complex diseases. Furthermore, increasing investments in biotechnology research and expanding clinical applications of epigenetic biomarkers are likely to create significant opportunities for innovation and long-term growth in this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Enzymes
• Instruments and Consumables
• Kits
• Reagents

By Application

• Oncology
• Non-Oncology

By Technology

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non-coding RNA
• MicroRNA Modification
• Chromatin Structures

By End User

• Academic and Research Institutes
• Pharmaceutical Companies and Biotechnology Companies
• Contract Research Organizations (CROs)

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, F Hoffmann La Roche Ltd, Novartis AG, Merck KGaA, Illumina Inc, Qiagen NV, Pacific Biosciences of California Inc, Bio Techne Corporation, Promega Corporation, Zymo Research Corporation, New England Biolabs Inc, Abcam plc, Active Motif Inc, Diagenode SA, GeneTex Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EPIGENETICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Enzymes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments and Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EPIGENETICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EPIGENETICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology
• 6.2. DNA Methylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Histone Methylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Histone Acetylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Large non-coding RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. MicroRNA Modification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Chromatin Structures Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EPIGENETICS MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Pharmaceutical Companies and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Contract Research Organizations (CROs) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL EPIGENETICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Application
  • 8.2.3 By Technology
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Application
  • 8.3.3 By Technology
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Application
  • 8.4.3 By Technology
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Application
  • 8.5.3 By Technology
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Application
  • 8.6.3 By Technology
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL EPIGENETICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 F. Hoffmann La Roche Ltd
  • 10.2.3 Novartis AG
  • 10.2.4 Merck KGaA
  • 10.2.5 Illumina Inc
  • 10.2.6 Qiagen N.V
  • 10.2.7 Pacific Biosciences Of California Inc
  • 10.2.8 Bio Techne Corporation
  • 10.2.9 Promega Corporation
  • 10.2.10 Zymo Research Corporation
  • 10.2.11 New England Biolabs Inc
  • 10.2.12 Abcam Plc
  • 10.2.13 Active Motif Inc
  • 10.2.14 Diagenode S.A
  • 10.2.15 GeneTex Inc